✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

For users who do not have sex frequently enough to justify daily PrEP, event-driven 2-1-1 dosing is a validated alternative for cisgender men who have sex with men (cisMSM) — two pills 2 to 24 hours before sex, one pill 24 hours later, and one more 24 hours after that. The total exposure across an encounter is four pills, often less than a week of daily PrEP, with HIV protection efficacy comparable to daily dosing in the population where it has been studied. It is the most rigorously evidenced alternative to daily PrEP.

But 2-1-1 is also the most misunderstood PrEP regimen. It is FDA-approved only for cisgender MSM, only with TDF/FTC (Truvada generics, Tenvir-EM, Ricovir-EM) — not with TAF/FTC (Descovy or Taficita), not for cisgender women, not for trans men with receptive vaginal exposure, and not for unpredictable last-minute encounters. The eligibility window is narrow, and within that window, the protocol is genuinely useful.

On-Demand PrEP (2-1-1): When Event-Driven Dosing Works and Who It’s Approved For

Reviewed by Morgan Ellis, Clinical Pharmacy Editor — MedsBase Medical Review Team. Last updated: 16 May 2026.

Quick Answer: Should You Use 2-1-1?

2-1-1 (also called “on-demand” or “event-driven” PrEP) is a validated alternative to daily PrEP for cisgender MSM with anal exposure risk, using TDF/FTC only (not TAF/FTC). The protocol: 2 pills 2 to 24 hours before sex, 1 pill 24 hours after first dose, 1 pill 24 hours after that. It is NOT approved for cisgender women, trans men with receptive vaginal exposure, or with TAF/FTC formulations. The timing requirement to take the loading dose 2+ hours before sex means it is unsuitable for unpredictable encounters. For everyone else, daily PrEP remains the standard.

How 2-1-1 Actually Works

2-1-1 is built around the pharmacokinetic profile of TDF/FTC (tenofovir disoproxil fumarate + emtricitabine). The 2-pill loading dose produces high tenofovir-diphosphate (TFV-DP) concentrations in colorectal tissue — the relevant compartment for anal sex exposure — within 2 to 24 hours. Subsequent single doses maintain that protective concentration through the period when HIV could establish infection from a recent exposure (typically 48 to 72 hours).

The protocol step-by-step:

• Step 1 (Loading dose): 2 pills of TDF/FTC 2 to 24 hours before the planned sexual encounter. The 2-hour minimum is critical — TFV-DP concentrations need time to build up in colorectal tissue. Taking the loading dose less than 2 hours before sex does not give the drug time to work.
• Step 2 (24-hour follow-up): 1 pill of TDF/FTC 24 hours after the loading dose (not after the sex; after the loading dose).
• Step 3 (48-hour follow-up): 1 pill of TDF/FTC 24 hours after Step 2 (i.e., 48 hours after the loading dose).

Total: 4 pills per encounter spread over approximately 48 to 50 hours.

Multiple encounters in close succession

If sex continues over a weekend trip or extended encounter, the protocol adapts:

• Take the loading dose 2 to 24 hours before the FIRST encounter.
• Continue 1 pill every 24 hours through the period of ongoing sexual activity.
• After the LAST sexual act, continue 1 pill at 24 hours and another at 48 hours — same final 2 pills as a single-encounter protocol.

For users with frequent sex (more than 2 encounters per week), the math starts favoring daily PrEP — you may be taking nearly daily pills anyway, with the added complexity of remembering the loading and tail doses.

What 2-1-1 is NOT

• NOT post-exposure prophylaxis (PEP). PEP is a 28-day course of three antiretrovirals starting within 72 hours of a known HIV exposure. 2-1-1 is pre-exposure — the loading dose precedes the exposure.
• NOT a one-pill solution. Patients sometimes mistakenly think the loading dose alone provides protection. It does not — the full 2-1-1 cycle is required.
• NOT compatible with last-minute hookups. The 2-hour minimum lead time is a hard requirement. If you cannot plan 2+ hours ahead, daily PrEP is the only protective option.

The Evidence: IPERGAY and Its Real-World Validation

The pivotal trial for 2-1-1 was IPERGAY (Intervention Préventive de l’Exposition aux Risques avec et pour les Gays), a French / Canadian double-blind randomised controlled trial published in NEJM in 2015.

• 400 cisgender MSM at high risk for HIV randomised to 2-1-1 TDF/FTC vs placebo.
• Mean follow-up 9.3 months; relative risk reduction in HIV acquisition was 86%.
• 2 HIV infections occurred in the active arm (both linked to non-adherence to the protocol); 14 infections in the placebo arm.
• Adverse events were comparable to placebo; no significant new safety signals beyond known TDF/FTC profile.

The IPERGAY open-label extension and the subsequent ANRS Prevenir cohort study extended the dataset to thousands of cisMSM with continued strong protection. Real-world effectiveness in France (where 2-1-1 has been widely adopted) has matched the trial efficacy.

Why this protocol works

The pharmacokinetic argument:

• The 2-pill loading dose produces colorectal tissue TFV-DP concentrations comparable to those achieved with 7 days of daily PrEP within 2 to 24 hours.
• The 24-hour and 48-hour tail doses maintain those concentrations through the typical 48 to 72-hour HIV infection window.
• Anal mucosa concentrates TFV-DP efficiently — even at the relatively low dosing of 2-1-1, intracellular concentrations meet or exceed the threshold needed to block HIV reverse transcription.

The same pharmacokinetic argument does NOT apply to vaginal tissue (which has different drug penetration characteristics), and the trial did not enroll cisgender women — which is why 2-1-1 is not approved for vaginal exposure.

Eligibility: Who Is 2-1-1 For?

Approved population

• Cisgender men who have sex with men (cisMSM) — the population studied in IPERGAY and its follow-ups.
• Transgender women — pharmacokinetic data is supportive but trial enrolment was limited; most guidelines extend approval based on pharmacokinetic equivalence.
• Anal exposure context — both receptive and insertive anal sex.
• Predictable encounters — the 2-hour minimum lead time is non-negotiable.

NOT approved for 2-1-1

• Cisgender women — vaginal tissue has different drug penetration. IPERGAY did not enroll cisgender women. Daily PrEP (TDF/FTC) is the only validated regimen for cisgender women.
• Transgender men with receptive vaginal exposure — same vaginal-tissue pharmacokinetic limitation.
• Patients on TAF/FTC (Descovy or Taficita) — TAF pharmacokinetics differ from TDF and the on-demand protocol has not been validated. Use daily TAF/FTC instead.
• Patients on hepatitis B treatment with tenofovir — discontinuing tenofovir between encounters risks HBV reactivation. Daily PrEP is mandatory.
• Patients with chronic kidney disease (eGFR <60) — though this is technically a TDF question rather than a 2-1-1 question, the cumulative TDF exposure of episodic high-dose 2-1-1 may be problematic.

Critical Don’ts

Don’t take the loading dose less than 2 hours before sex

This is the most common protocol failure. The 2-hour minimum is the time required for TFV-DP to build up in colorectal tissue. Sex that happens before that window has not been protected — even though the patient took the pills.

If you find yourself in a situation where sex is imminent and you have not taken a loading dose, do NOT rely on a quick 2-pill dose for protection. The protocol does not retroactively apply. Either: (1) decline the encounter, (2) use a barrier method, (3) consider PEP if a known HIV-positive partner is involved.

Don’t skip the tail doses

The 24-hour and 48-hour pills are part of the protocol. Taking only the loading dose, or only the loading + 24-hour doses, does not provide validated protection. The full 2-1-1 cycle is required.

Don’t combine with TAF/FTC

Switching mid-encounter from TDF/FTC to TAF/FTC — for example, finishing a 2-1-1 cycle and then taking daily Descovy — has not been studied and creates an unpredictable pharmacokinetic transition. Pick one regimen and stay with it.

Don’t use 2-1-1 if you take PrEP >3 times per week anyway

The math doesn’t favor it. At 3+ encounters per week, 2-1-1 will require ~12+ pills, comparable to a week of daily PrEP at 7 pills. The added complexity of remembering the loading and tail doses is not worth the modest pill reduction. Daily PrEP is the cleaner choice.

Don’t use 2-1-1 in cisgender women or for vaginal exposure

This bears repeating because it is the most consequential misunderstanding. Vaginal-tissue pharmacokinetics are not addressed by IPERGAY, and the protocol does not safely transfer. Cisgender women on PrEP for vaginal exposure must use daily TDF/FTC.

Practical Scenarios

Scenario 1: Planned weekend hookup

You plan to meet a new partner Friday night. You eat dinner at 8 pm, and your encounter is scheduled for around 11 pm.

Take the 2-pill loading dose with dinner at 8 pm (3 hours before sex — well within the 2-hour minimum, well within the 24-hour maximum). Sex happens at 11 pm. Take 1 pill at 8 pm Saturday night. Take 1 pill at 8 pm Sunday night. Done. Total: 4 pills.

Scenario 2: Weekend trip with the same partner

You take a 3-day vacation with a sexual partner. Sex Friday night, Saturday afternoon, Saturday night, Sunday morning.

Take the 2-pill loading dose 2+ hours before the Friday encounter. Continue 1 pill every 24 hours through the trip (Saturday, Sunday). After the last encounter (Sunday morning), the tail extends to Monday morning and Tuesday morning. Total: roughly 6 to 8 pills depending on exact timing.

Scenario 3: Last-minute encounter (no PrEP loaded)

You meet someone at a bar and they want to come home with you in 30 minutes.

You cannot use 2-1-1 — the 2-hour minimum lead time has not been met. Options: (1) use a barrier method (condom); (2) decline the encounter; (3) if a known HIV-positive partner with unsuppressed viral load, take PEP within 72 hours and continue 28 days.

Scenario 4: Switching from daily PrEP to 2-1-1

Some users with infrequent encounters consider transitioning. The transition is straightforward — finish your current daily PrEP, then begin 2-1-1 dosing as encounters occur. There is no specific overlap or washout required. For users already protected by daily PrEP at the time of a planned encounter, 2-1-1 dosing is not needed during the encounter — they remain protected by their daily regimen.

Scenario 5: TAF/FTC user wanting on-demand

If you are currently on Descovy or Taficita and want to switch to on-demand 2-1-1, you must first switch to TDF/FTC (Tenvir-EM, Ricovir-EM, or US generic Truvada). 2-1-1 is not validated with TAF/FTC. See our switching Truvada to Descovy guide (in reverse) for the renal and bone implications of switching back from TAF to TDF.

Pricing and Pill Math

For low-frequency users, the cost savings are substantial; for users approaching daily-frequency encounters, the savings disappear and daily PrEP becomes the cleaner choice. Pricing is approximate and varies with formulary, supplier, and region.

Sourcing Considerations

The TDF/FTC formulations compatible with 2-1-1 include:

• Tenvir-EM — Cipla generic TDF 300 mg + FTC 200 mg. Widely used internationally.
• Ricovir-EM — Hetero generic TDF/FTC.
• Tavin-EM — alternative TDF/FTC generic.
• PrEP Starter Pack — Tenvir-EM + Doxycycline (Doxy-PEP for STI prevention).

For comprehensive sourcing context see our buying PrEP online guide.

Frequently Asked Questions

Can I use 2-1-1 PrEP if I’m a cisgender woman?

No. 2-1-1 is not approved or validated for cisgender women because the IPERGAY trial did not enrol women and vaginal-tissue pharmacokinetics of TDF differ from colorectal-tissue pharmacokinetics. Cisgender women on PrEP must use daily TDF/FTC (Truvada generics, Tenvir-EM, or Ricovir-EM).

Can I use Descovy for 2-1-1?

No. TAF/FTC (Descovy or Taficita) has not been studied or validated for on-demand 2-1-1 dosing. The pharmacokinetics of TAF differ from TDF — intracellular concentration ramping is slower, and the established on-demand protocol may not produce protective drug levels in the 2 to 24 hour window. Stay on TDF/FTC for 2-1-1.

What if I take the loading dose less than 2 hours before sex?

You are not protected by the 2-1-1 protocol. TFV-DP tissue concentrations are not yet at protective levels. Options: (1) use a barrier method during the encounter; (2) postpone the encounter; (3) if a confirmed high-risk exposure occurs, consider PEP (3-drug regimen within 72 hours).

What if I forget the 24-hour or 48-hour follow-up pill?

The closer to the original schedule, the better. If you miss the 24-hour pill, take it as soon as you remember (up to about 36 hours past the loading dose), then continue with the 48-hour pill on the original schedule. Missing a pill substantially blunts protection and the protocol no longer reads as fully validated — discuss with a clinician about whether daily PrEP would be a better long-term choice.

How does 2-1-1 compare to long-acting injectable cabotegravir (Apretude)?

Different mechanisms. Apretude is a bi-monthly intramuscular injection providing continuous protection without daily dosing concerns. 2-1-1 is event-driven oral dosing. Apretude is more reliable for users who cannot plan 2+ hours ahead but requires consistent clinic visits and is more expensive. 2-1-1 is cheaper and more flexible but requires planning capacity. The choice depends on lifestyle.

If my partner is HIV-positive but virally suppressed (U=U), do I still need 2-1-1?

The U=U (Undetectable = Untransmittable) consensus is that a sexual partner with HIV and sustained undetectable viral load (continuously below 200 copies/mL on antiretroviral therapy) does not sexually transmit HIV. In a stable relationship with U=U partner status confirmed by recent viral load testing, PrEP may not be strictly necessary. Many users continue PrEP anyway because of: (1) testing intervals between viral load checks, (2) external partner uncertainty, (3) personal preference for layered protection.

Does 2-1-1 protect against STIs?

No. PrEP — daily or on-demand — protects against HIV only. Other STIs (gonorrhea, chlamydia, syphilis, herpes) require separate prevention strategies including condoms, regular testing, and increasingly Doxy-PEP (doxycycline 200 mg within 72 hours after sex). See the PrEP STI testing monitoring guide.

What about combining 2-1-1 with Doxy-PEP?

The two are independent — 2-1-1 prevents HIV; Doxy-PEP (doxycycline 200 mg within 72 hours of sex) reduces bacterial STI transmission. They can be combined without interaction issues. For users who use 2-1-1 PrEP, adding Doxy-PEP for STI protection is increasingly common. The PrEP Starter Pack includes both components.

How does 2-1-1 affect my standard PrEP monitoring schedule?

The monitoring cadence is the same as daily PrEP: quarterly HIV testing, quarterly STI screen, renal function at baseline and every 6 to 12 months, hepatitis testing at baseline. Episodic 2-1-1 dosing does not reduce these requirements — HIV exposure happens during each encounter, and the testing window for incident infection is the same.

The Bottom Line

2-1-1 on-demand PrEP is a well-evidenced, cost-effective option for cisgender MSM with anal exposure risk and predictable enough timing to load 2+ hours before sex. For this population, the protection is comparable to daily PrEP at a fraction of the pill cost. For everyone else — cisgender women, trans men with vaginal exposure, TAF/FTC users, hepatitis B carriers, and users with unpredictable encounters — daily PrEP remains the only validated option.

The biggest practical mistake is the 2-hour minimum timing failure. The protocol does not retroactively work; the loading dose must precede sex by 2 to 24 hours. For users who cannot plan ahead reliably, the choice is daily PrEP or layered protection (barrier methods, vaccination, U=U partner).

For ongoing supply and product details see our verified PrEP options: Tenvir-EM, Ricovir-EM, Tavin-EM, and the PrEP Starter Pack (with Doxy-PEP). Related reading: buying PrEP online, missed PrEP dose restart protocols, switching Truvada to Descovy, generic Descovy patent expiry, Truvada vs Descovy comparison, PrEP side effects in the first 90 days, PrEP STI testing, and the PrEP primer.

Every order is covered by our Reshipment Assurance Policy: if your parcel does not arrive within 20 business days of dispatch (EMS or ITPS), we send a replacement at no extra cost.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.